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Abstract The organic acidurias D-2-hydroxyglutaric acidu-
ria (D-2-HGA), L-2-hydroxyglutaric aciduria (L-2-HGA),
and combined D,L-2-hydroxyglutaric aciduria (D,L-
2-HGA) cause neurological impairment at young age.
Accumulation of D-2-hydroxyglutarate (D-2-HG) and/or L-
2-hydroxyglutarate (L-2-HG) in body fluids are the bio-
chemical hallmarks of these disorders. The current review
describes the knowledge gathered on 2-hydroxyglutaric
acidurias (2-HGA), since the description of the first patients
in 1980. We report on the clinical, genetic, enzymatic and
metabolic characterization of D-2-HGA type I, D-2-HGA
type II, L-2-HGA and D,L-2-HGA, whereas for D-2-HGA
type I and type II novel clinical information is presented
which was derived from questionnaires.
Abbreviations
2-HG 2-hydroxyglutaric acid












L2HGDH gene encoding L-2-hydroxyglutarate
dehydrogenase
D,L-2-HGA combined D,L-2-hydroxyglutaric aciduria




L-malDH L-malate dehydrogenase enzyme
MIM Mendelian Inheritance in Man
CSF cerebrospinal fluid
Introduction
Gregersen et al (1977) were the first to identify enantiomeric
D- and L-2-hydroxyglutaric acids (D-2-HG and L-2-HG) as
normal constituents of human urine. Three years later,
two novel inborn errors of metabolism were simulta-
neously reported in the Journal of Inherited Metabolic
Disease. Chalmers et al (1980) identified a patient with
D-2-hydroxyglutaric aciduria (D-2-HGA), while Duran et
al (1980) described a case of L-2-hydroxyglutaric aciduria
(L-2-HGA), landmark publications that identified the meta-
bolic hallmarks (D- and L-2-HG) in these disorders. Muntau
et al (2000) described a third biochemical variant of 2-
hydroxyglutaric aciduria (2-HGA) when they reported three
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patients with elevated urinary D- and L-2-HG, denoted by
these authors as “combined D,L-2-hydroxyglutaric aciduria”
(D,L-2-HGA). Major milestones in research on these disor-
ders came with gene discovery: D2HGDH encoding D-2-
hydroxyglutarate dehydrogenase (D-2-HGDH)(Achouri et al
2004) and L2HGDH encoding L-2-hydroxyglutarate dehydro-
genase (L-2-HGDH)(Rzem et al 2004; Topcu et al 2004). In
many D-2-HGA, and the majority of L-2-HGA patients,
genetic characterization revealed pathogenic mutations in
these genes (Struys et al 2005b; Steenweg et al 2010). None-
theless, in fully one-half of D-2-HGA patients no mutations in
D2HGDH were detected (Kranendijk et al 2010a). Subse-
quently, we described gain-of-function mutations in isocitrate
dehydrogenase 2 (IDH2) which proved causative for the D-2-
HG accumulation in previously unclassified D-2-HGA
patients (Kranendijk et al 2010b). In sum, the preceding
decade has provided tremendous advances in our under-
standing of the inborn 2-hydroxyglutaric acidurias, which will
undoubtedly provide a solid foundation fromwhich to develop
novel and effective treatment strategies.
This Review evaluates metabolic, enzymatic, genetic and
clinical progress in our understanding of the rare inborn
organic acidurias D-2-HGA, L-2-HGA and D,L-2-HGA.
Future research and therapeutic perspectives are also briefly
discussed.
Enantiomeric D,L-2-hydroxyglutaric acid and its origin
The five-carbon dicarboxylic acid 2-hydroxyglutaric acid
(2-HG) possesses a hydroxyl group at the second carbon
(Fig. 1) which yields a chiral center. Accordingly, two three-
dimensional (3D) structures exist, including D-2-HG and L-
2-HG, which represent “non-superimposable” mirror
images (Fig. 2). Systemic names are (R)-2-hydroxypentane-
dioic acid and (S)-2-hydroxypentanedioic acid, respectively,
for D- and L-2-HG. Whereas enantiomers share identical
chemical and physical properties (melting point, mass, solu-
bility and pKa), their differing 3D-structures result in consid-
erable differences in enzymatic and molecular properties.
Pilot studies employing stable isotope labeled [13C6]glu-
cose or [2H5]glutamic acid with D-2-HGA lymphoblast cell
cultures revealed that mitochondrial 2-ketoglutarate (2-KG),
a tricarboxylic acid (TCA) cycle intermediate, can be
metabolized to D-2-HG (Struys et al 2004b). Subsequent
studies documented the existence of hydroxyacid-oxoacid
transhydrogenase (HOT) activity in human liver and fibro-
blasts, representing the first demonstration of a human en-
zyme whose catalytic function was production of D-2-HG
(Struys et al 2005c). HOT catalyzes the conversion of γ-
hydroxybutyrate (GHB) to succinic semialdehyde (SSA) with
a stoichiometric production of D-2-HG from 2-KG (Fig. 3).
Similarly, pilot studies of L-2-HGA lymphoblasts incubated
with [13C6]glucose and [
2H5]glutamic acid further delineated
that mitochondrial 2-KG is the precursor of L-2-HG (Struys et
al 2007). Currently, the only enzyme known to generate L-2-
HG from 2-KG in human is L-malate dehydrogenase (L-
malDH) (Fig. 3), whose primary catalytic function is the
interconversion of L-malate to oxaloacetate (Rzem et al 2007).
The diagnosis of 2-hydroxyglutaric aciduria
The differential diagnosis of 2-hydroxyglutaric aciduria
begins with the clinical evaluation of a patient with unex-
plained developmental delay and/or other neurological dys-
function of unknown etiology, raising suspicion for a
metabolic disorder. Provisional diagnosis of the disorder is
occasionally suggested by abnormal brain MRI findings.
Urinary organic acid screening with gas chromatography-
mass spectrometry (GC-MS), performed in multiple metabolic
centers, can reveal increased 2-HG, but the chiral con-
figuration remains to be determined. Although the clin-
ical presentation often can suggest either D-2-HGA or
Fig. 1 2-hydroxyglutaric acid with a chiral center at the 2nd carbon (*)
Fig. 2 Enantiomers D- and L-2-hydroxyglutaric acid (D-2-HG and L-
2-HG, systemic IUPAC names included)
Fig. 3 Enzymes L-malDH and HOT are responsible for production of
D-2-HG and L-2-HG from 2-KG
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L-2-HGA, chiral differentiation performed with GC-MS
or liquid chromatography-tandem mass spectrometry
(LC-MS/MS) is mandatory for the correct differential
diagnosis (Gibson et al 1993a; Struys et al 2004a).
Additionally, amino acid analysis in plasma and/or ce-
rebrospinal fluid (CSF) may identify elevated lysine in
L-2-HGA. Subsequently, enzymatic and genetic charac-
terization can confirm L-2-HGA, as well as differentiate
between the type I or II form of D-2-HGA, representing
important information for genetic counseling and future
prenatal diagnosis (Steenweg et al 2010; Kranendijk et
al 2010a, b). While elevated L-2-HG levels are specific
for L-2-HGA and are also detected in D,L-2-HGA, D-2-
HG can be elevated in a number of other disorders in
addition to D-2-HGA type I and type II, discussed in a
separate section of this Review. Some authors have
suggested that a potential false positive diagnosis of
D- or L-2-HGA may occur with improperly preserved
urine samples linked either to nonenzymatic conversion
of 2-KG to D/L-2-HG, or via excretion of D/L-2-HG
from bacterial or fungal growth in the urine specimen
(Kumps et al 2002). We have not, however, experienced
this occurrence in our laboratory.
D-2-hydroxyglutaric aciduria type I and II
(MIM# 600721 and MIM# 613657)
Recent studies have documented the presence of two groups,
D-2-HGA types I and II, of roughly equal size and encom-
passing >95% of all patients. D-2-HGA type I associates with
mutations in the D2HGDH gene encoding D-2-hydroxygluta-
rate dehydrogenase (D-2-HGDH) which lead to impaired
enzyme function (Kranendijk et al 2010a). The type II disorder
derives from specific gain-of-function mutations in the IDH2
gene which result in accumulation of D-2-HG (Kranendijk et
al 2010b). Both gene defects lead to supraphysiological accu-
mulation of D-2-HG in urine, plasma and CSF, representing
the biochemical hallmarks of the diseases.
Clinical manifestations of D-2-HGA
D-2-HGAwas recognized as a distinct neurometabolic disor-
der withmild and severe phenotypes in the late 1990s (Van der
Knaap et al 1999a, b). The clinical phenotype encompassed
epilepsy, hypotonia and psychomotor retardation as the pri-
mary features. With the genetic identification of type I
(D2HGDH mutations, MIM# 600721) and type II (gain-of-
function mutations in IDH2, MIM# 613657) disorders in
2010, it became clear that studies from 1999 encompassed
heterogeneous groups of both subtypes of patients, as well as
combined D,L-2-HGA patients, which likely led to the
heterogeneous description of mild and severe phenotypes.
Herein we present novel clinical features in 14 type I and
19 type II patients based on clinical questionnaires. The age
of onset for type I patients is generally within the first six
years, whereas for type II the age of onset was within two
years (Table 1). Cardinal clinical manifestations for both
disorders include developmental delay, hypotonia and seiz-
ures, although seizures occur with higher frequency in type
II patients (Table 1). All type II patients were developmen-
tally delayed, and the delays were more severe than those
observed in type I patients. In 9 of 19 type II patients
cardiomyopathy (primarily dilated, but in one case hypertro-
phic) was observed, a feature absent from the type I phenotype.
The course of the type II disease is primarily progressive, but a
static disease, or even improvement have been reported in a
limited number. Life expectancies for type II patients may
range from several months to early adulthood (Table 1). Con-
versely, for type I patients the life expectancy remains unde-
fined. One patient died in the third week of life with a diagnosis
of necrotizing enterocolitis at post mortem examination, while
three others are currently 5-12 years of age.
The disorders appear panethnic, and consanguinity is
frequent in the type I disorder while essentially absent in
type II families. Clinical heterogeneity of previously pub-
lished cases showed alikeness with the symptoms summa-
rized in Table 1. Additional clinical features variably
reported have included macrocephaly, dysmorphic features
and cerebral visual failure. These patients were not, however,
differentiated as D-2-HGA type I or type II disease. Cardio-
myopathy was exclusive to type II patients in our data
(Table 1), however in one reported unrelated type I patient
(homozygous for c.458T>C; p.Met153Thr in D2HGDH) an
increased cardiothoracic index and hypertrophic cardiomyop-
athy was documented (Haliloglu et al 2009), which is until
now an isolated finding.
Neuroimaging performed in D-2-HGA patients was pre-
dominantly instituted prior to knowledge of the underlying
molecular defects. The clinical features in these undifferen-
tiated patients included enlargement of the lateral ventricles,
enlarged frontal subarachnoid spaces, subdural effusions,
subependymal pseudocysts, signs of delayed cerebral mat-
uration and multifocal cerebral white-matter abnormalities
(Van der Knaap et al 1999a, b). An ongoing imaging study
is underway in our laboratories to more accurately define the
CNS abnormalities associated with the type I and II disor-
ders. Finally, an intriguing study of 4.5-year-old female
monozygotic twins affected with type I disease (Misra et
al 2005) revealed one with multiple congenital anomalies,
severe developmental delay, and abnormal neuroradiological
findings, while the other reached all major motor and
language milestones appropriately associated with a generally
uncomplicated clinical course. The latter imply that postzy-
gotic genetic alterations and/or environmental factors
influence the phenotypic outcome of the type I disease.
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D2HGDH mutations: the molecular basis of D-2-HGA type I
Employing DEAE-sepharose chromatography combined
with spectrophotometric and radioactive detection, Achouri
and co-workers isolated enzymes from rat liver in order
to screen for a dehydrogenase acting upon D-2-HG
(Achouri et al 2004). Van Schaftingen and coworkers
subsequently identified the D2HGDH gene (GeneBank
728294, NM_152783, MIM# 609186), which encodes a
D-2-hydroxyglutarate dehydrogenase (D-2-HGDH) with
considerable specificity for D-2-HG. Subsequent detection
of D2HGDH mutations in patients with D-2-HGA confirmed
the identity of this cDNA and documented the genetic lesions
(Misra et al 2005; Struys et al 2005a, b; Haliloglu et al 2009;
Kranendijk et al 2010a; Pervaiz et al 2011). Twenty six
patients have thus far been identified, harboring 31 mutations
spread across the D2HGDH coding sequence (Fig. 4). Eleven
mutations are predicted to result in truncated enzymes, while
the remaining twenty missense mutations alter amino
acids conserved across species, which suggests pathogenicity.
As well, limited overexpression studies ofmutated alleles have
confirmed their pathogenicity (Struys et al 2005b).
Accordingly, patients harboring pathogenic homozygous,
or compound heterozygous mutations, in the D2HGDH gene
are denoted D-2-HGA type I (∼50% of the D-2-HGA
population), and the autosomal-recessive inheritance pattern
has been confirmed by genetic characterization of parental
DNA samples.
IDH2 mutations: the molecular basis of D-2-HGA type II
Various investigators working in the field of cancer genetics
identified an increased incidence of heterozygous mutations
in isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) in select-
ed individuals with carcinoma. These alleles induced novel
enzyme functions in IDH1 and IDH2, namely the newfound
capacity to convert 2-KG to D-2-HG, and resulting in supra-
physiological accumulation of D-2-HG (Parsons et al 2008;
Dang et al 2009; Ward et al 2010). These data led our group
to hypothesize that IDH mutations might represent the
genetic underpinning of D-2-HGA, and we subsequently
identified germline heterozygous IDH2 mutations in a num-
ber of D-2-HGA patients (GeneBank 3418, NM_002168,
MIM# 147650)(Kranendijk et al 2010b). These novel
molecular events thereby represent the second D-2-HGA
defect, denoted as D-2-HGA type II. We have subsequently
identified 14 patients carrying the heterozygous c.419G>A,
p.Arg140Gln mutation (IDH2wt/R140Q), in addition to one
patient who was heterozygous for c.418C>G, p.Arg140Gly
(IDH2wt/R140G). In the DNA derived from 24 patients, these
gain-of-function mutations represent ∼50% of the D-2-HGA
population. Moreover, IDH2 alleles were not detected in
8 of 9 sets of parents, suggesting de novo occurrence and
an autosomal dominant pattern of inheritance. Of interest, in
one family three subsequent pregnancies were diagnosed as
affected by D-2-HGA type II (genetic diagnosis in DNA iso-
lated from amniocytes), which suggested germline mosaicism
Table 1 Clinical observations in
D-2-HGA type I and type I
*postmortem diagnosis of nec-
rotizing enterocolitis
Symptoms D-2-HGA type I D-2-HGA type II
Number of patients 14 19
Age onset (yr) Mean 1 ¼
Range 0-6 0-2
Signs during disease Developmental delay 78 (11 pts.) 100 (19 pts.)
(% of type I or type II) - 3 pts. unaffected - 0 pts. unaffected
- 5 pts. mild - 2 pts. mild
- 3 pts. moderate - 6 pts. moderate
- 3 pts. severe - 11 pts. severe
Hypotonia 57 (8 pts.) 89 (17 pts.)
Seizures 29 (4 pts.) 79 (15 pts.)
Cardiomyopathy 0 47 ( 9 pts.)
- 7 pts. dilated
- 1 pt. hypertrophic
- 1 pt. unknown
Alive (yr) Mean age 8 (n03) 8.4 (n010)
Range 5, 7, 12 2.8-19
Died (yr) Mean age 3 weeks* (n01) 6.5 (n09)
Range - 0.3-22
Unknown n010 -
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in the mother who was subsequently confirmed to harbor
somatic mosaicism in blood.
Currently, 95 D-2-HGA patients have been detected (in-
cluding unpublished patients identified in our laboratories),
most of whom were diagnosed prior to identification of the
molecular lesions (Table 2). For ∼50% of those patients,
genetic characterization revealed 26 type I and 24 type II
patients. In two cases no mutations were found in either
gene (D2HGDH or IDH2), and thus the underlying etiology
remains unknown. Several patients have previously been
reported as D-2-HGA who showed (to lesser extent) in-
creased L-2-HG as well, denoted “combined D,L-2-HGA”,
which will be discussed later in detail. Another subset of D-
2-HGA patients, without D2HGDH or IDH2 mutations, but
with skeletal dysplasia is discussed more completely later in
this Review.
Metabolism in D-2-HGA
Different catalytic mechanisms underlie D-2-HG accumula-
tion in the D-2-HGA type I and II disorders. HOT (EC
1.1.99.24) converts 2-KG to D-2-HG (Fig. 5)(Struys et al
2005c), and currently there is no known physiological func-
tion for D-2-HG in human metabolism. To maintain carbon
balance and avoid intoxication, D-2-HG is interconverted to
2-KG via D-2-HGDH (EC 1.1.99.-). Our laboratory demon-
strated impaired D-2-HGDH activity in lymphoblasts and
fibroblasts derived from type I patients, whereas this activity
was normal in type II cells (Table 3) (Wickenhagen et al
2009; Kranendijk et al 2010a). Thus, D-2-HG accumulation
in the type I disease is directly correlated with deficient D-2-
HGDH activity.
In the type II disorder, heterozygous mutations detected
in isocitrate dehydrogenase 2 (IDH2, EC 1.1.1.42) at residue
140 replaces arginine by glutamine or glycine (Kranendijk
et al 2010b). While wild type IDH2 reversibly catalyzes the
conversion of isocitrate to 2-KG using the NADP(H) cou-
ple, IDH2wt/R140Q-mutant acquires the enzymatic capacity to
convert 2-KG to D-2-HG using NADPH as a hydride
donor (Fig. 6). Along these lines, an eight-fold increase
of IDH2wt/R140Q reaction velocity was detected in lym-
phoblasts obtained from type II patients in comparison
to control and type I cells (Table 3) (Kranendijk et al 2011).
We have speculated that the capacity of active D-2-HGDH is
insufficient to metabolize the excess D-2-HG formed by gain-
of-function IDH2wt/R140Q.
Different mechanisms leading to the production of D-2-
HG in the type I and II disorders appear to be reflected in the
absolute concentrations of this metabolite in physiological
fluids and intracellularly in cultured lymphoblasts (Table 4)
(Kranendijk et al 2010a, b; Kranendijk et al 2011). D-2-HG
levels are 2 to 8-fold higher in type II as opposed to type I
patients, although the absolute level of D-2-HG is highly
Fig. 4 Mutations reported in D2HGDH (Misra et al 2005; Struys et al
2005a, b; Haliloglu et al 2009; Kranendijk et al 2010a; Pervaiz et al 2011)
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increased in all fluids, or cells, that were examined. Metab-
olite concentrations in plasma exceed those in CSF for both
groups. Moreover, extensive metabolic screening (e.g.,
organic acids, amino acids, acylcarnitines, GABA) has
been performed in multiple physiological fluid samples
derived from patients, yet the only consistent biochemical
marker remains D-2-HG in both subtypes, with normal levels
of L-2-HG in all instances.
Pathophysiology of D-2-HGA
Although genetically distinct, D-2-HGA types I and II share
accumulation of D-2-HG in physiological fluids, as well as
common clinical features, but without cardiomyopathy in
type I. These observations suggest that the metabolite D-2-
HG contributes to the pathophysiology associated with the
clinical features of developmental delay, hypotonia and
seizures observed in both groups. Overproduction of D-2-
HG likely begins in the mitochondria, since D-2-HGDH and
IDH2 are mitochondrial enzymes. Intracellular/mitochondrial
D-2-HG concentrations are unknown, but plasma concentra-
tions are often used as a surrogate measure. Plasma D-2-HG
concentrations are 30-840 fold increased in patients (26-
757 μM)(Table 4). The mean plasma levels are ∼5 times
higher in type II than in type I patients with little overlap of
the ranges. Since the frequency and severity of developmental
delay, hypotonia and seizures observed in type II patients are
slightly higher than those observed in the type I disorder
(Table 1), there appears to be a correlation between increasing
D-2-HG concentrations and disease severity.
In vitro studies have revealed both cyto- and neurotoxic
effects of high levels of D-2-HG. Along these lines, expo-
sure of tissues from rat and chick to increasing D-2-HG
concentrations downregulated the creatine kinase, complex
IVand complex Venzymes (da Silva et al 2002; Kölker et al
2002; da Silva et al 2003a, b, 2004). Additionally, high
levels of D-2-HG induced oxidative stress and markedly
impaired mitochondrial energy metabolism in several model
systems in vitro (Kölker et al 2002; Latini et al 2003b,
2005). Neurotoxic effects of increased D-2-HG was revealed
by increased synaptosomal glutamate uptake without alter-
ation in other synaptosomal parameters studied (Junqueira et
al 2004), as well as by NMDA receptor activation in primary
neuronal cultures (Kölker et al 2002).
The IDH-mutated gain-of-function allele received con-
siderable attention in the broad areas of cancer research,
since it was first identified in brain tumors (Parsons et al
2008). Of interest, neoplastic disorders have not been
reported in either D-2-HGA type I or II patients, which
Table 2 Overview of number of D-2-HGA patients divided in specific groups
D-2-HGA Remarks References
Type I (n026) 1 patient affected with comorbid Sanfilippo
syndrome type C
Gibson et al 1993b; Craigen et al 1994; Van der Knaap et al 1999b;
Misra et al 2005; Struys et al 2005a; b; Haliloglu et al 2009;
Kranendijk et al 2010a; Pervaiz et al 2011
Type II (n024) 15 published pts. Geerts et al 1996; Amiel et al 1999; Van der Knaap et al 1999a; b;
Clarke et al 2003; Kranendijk et al 2010b9 unpublished pts.*
Undifferentiated (n043) DNA unavailable for D2HGDH and IDH2
sequencing
Chalmers et al 1980; Nyhan et al 1995; Sugita et al 1995;
Baker et al 1997; Wagner et al 1998; Van der Knaap
et al 1999a; b; Eeg-Olofsson et al 2000; Kwong et al 2002;
Wang et al 2003; Mahfoud et al 2009
18 published pts.
25 unpublished pts.*
Unknown (n02) D-2-HGA type I and type II were excluded:
no mutations detected in D2HGDH or IDH2
Kranendijk et al 2010b
Combined Increased D-2-HG and L-2-HG Wagner et al 1998; Amiel et al 1999; Van der Knaap et al 1999a; b;
Muntau et al 2000; Wajner et al 2002; Read et al 2005D,L-2-HGA (n011) 6 published pts.
5 unpublished pts.*
Skeletal dysplasia (n06) 3 published pts. Talkhani et al 2000; Honey et al 2003; Bayar et al 2005
3 unpublished pts.*
* Unpublished patients have been diagnosed in our laboratory
Fig. 5 D-2-HG is formed from 2-KG via HOT. D-2-HGDH catalyzes
the conversion of D-2-HG to 2-KG. D-2-HG accumulates in D-2-HGA
type I patients when D-2-HGDH is impaired
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would argue against the hypothesis proposed by others that
D-2-HG is an onco-metabolite (Dang et al 2009; Ward et al
2010). On the other hand, Zhao et al (2009) demonstrated
that the hypoxia-inducible factor subunit-1α (HIF-1α), a
transcription factor that facilitates tumor growth in the pres-
ence of low oxygen, was higher in human gliomas harboring
an IDH1 mutation than tumors lacking a mutation. Xu et al
(2011) reported that D-2-HG acts as a competitive inhibitor
of multiple 2-KG-dependent dioxygenases which leads to a
genome-wide alteration in histone and DNA methylation
patterns. These authors suggested that the latter may hypo-
thetically contribute to tumorigenesis through alterations of
epigenetic control and changes in stem cell differentiation.
The preceding observations, focused on epigenetic effects
and outcomes, could be in line with our findings in mono-
zygotic twins affected with D-2-HGA type I (Misra et al
2005). Random affects of gene methylation combined with
environmental influences during pregnancy and/or after
birth might influence phenotypic outcomes, although the
twins are genetically identical.
Therapeutic perspectives
There is currently no effective therapeutic intervention for
D-2-HGA. Addition of FAD to purified D-2-HGDH
enzymes did not result in increased activity (Achouri et al
2004). A therapeutic trial with riboflavin has not been
attempted, but might be beneficial since the DNA sequence
of D2HGDH belongs to a family of enzymes that use FAD
as a cofactor. In the type II disease, inhibition of IDH2-
mutants with oxaloacetate led to decreased D-2-HG produc-
tion in patient lymphoblast lysates (Kranendijk et al 2011).
Inhibition with highly IDH2-mutant specific substrates/
drugs may represent a viable therapeutic strategy in patients.
L-2-hydroxyglutaric aciduria (MIM# 236792)
L-2-hydroxyglutaric aciduria (L-2-HGA) is an autosomal
recessive encephalopathy. It is a “disorder of metabolite
repair” (Van Schaftingen et al 2008), but the pathophysiology
of the white matter abnormalities is poorly understood.
Clinical manifestations of L-2-HGA
Several clinical reports of L-2-HGA have appeared since the
index case in 1980 (Barth et al 1993; Barbot et al 1997;
Achouri et al 2004; Topcu et al 2005; Steenweg et al 2009,
2010). The phenotype is homogeneous (Table 5). Steenweg
and co-workers described the largest cohort of 106 patients.
An insidious onset of disease starting in childhood, devel-
opmental delay, epilepsy and cerebellar ataxia were the
cardinal clinical signs (Steenweg et al 2010). Accordingly,
the course of the disease is slowly progressive. Therefore,
mild L-2-HGA patients often remain undiagnosed until
adolescence or even adulthood. Virtually all patients display
delayed mental and motor development, and about two-third
of them epilepsy and cerebellar dysfunction. In about half of
patients, macrocephaly and extrapyramidal symptoms
including tremor and dystonia are observed. Hypotonia
was most prevalent in the earlier stages and spasticity in
the latter stages of disease in their cohort. Neurological
decompensation (e.g., loss of milestones, such as unassisted
walking and the development of speech deficits) was also
present in a quarter of the patients.
Steenweg et al (2009) systematically evaluated the brain
MRIs of 56 patients, and found a highly characteristic
pattern of MRI abnormalities in L-2-HGA including abnor-
malities of the subcortical cerebral white matter dentate nu-
cleus, globus pallidus, putamen, and caudate nucleus. These
results correlated well with previous case reports of L-2-HGA
patients (Barth et al 1993; Barbot et al 1997; Topcu et al
Table 3 Enzyme activities
of D-2-HGDH and IDH2wt/R140Q
in D-2-HGA cell lines
fib. 0 fibroblasts; lyb. 0
lymphoblasts (Wickenhagen
et al 2009; Kranendijk
et al 2010a, 2011)
D-2-HGDH fib.
(pmol h-1 mg prot.-1)
D-2-HGDH lyb.
(pmol h-1 mg prot.-1)
IDH2wt/R140Q lyb.
(pmol h-1 mg prot.-1)
mean (n); range mean (n); range mean (n); range
Controls 456 (5); 247-665 1409 (5); 273-2545 1800 (5); 1400-2100
D-2-HGA type I 22 (5); 0-41 12 (2); 2, 21 1900 (2); 1900, 1900
D-2-HGA type II 338 (14); 204-634 1062 (4); 570-1503 14400 (5); 12000-18800
Fig. 6 Novel IDH2-mutant gain-of-function produces D-2-HG from
2-KG in addition to production of D-2-HG via HOT. It is hypothesized
that D-2-HGDH cannot fully metabolize all of the generated D-2-HG,
resulting in D-2-HG accumulation in D-2-HGA type II
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2005). As the disease progresses, abnormalities of white
matter and basal ganglia signal intensities became more dif-
fuse, followed by cerebral white matter atrophy. Barbot et al
(1997) found a strong correlation between the severity of
clinical manifestations and the extent of the MRI lesions in a
cohort of six patients, but this correlation was not noted by
Steenweg et al (2009).
Acute metabolic derangement has not been reported in L-
2-HGA, although rapid deterioration has been noted in nine
cases, in relation to brain tumors (Moroni et al 2004;
Haliloglu et al 2008; Aghili et al 2009). Additionally,
Vilarinho et al (2005) reported two children and one adult
with brain astrocytomas in their series of 21 L-2-HGA
patients of Portuguese descent, while Steenweg et al
(2009) mentioned only a single case affected with a tumor
in the cerebral cortex in their cohort of 56. The preceding 13
cases of patients with brain tumors suggest an association of
L-2-HGA with CNS tumors, which has led to speculation
that L-2-HG may predispose to oncogenesis. Non-CNS
tumors have been documented in L-2-HGA as well, includ-
ing a bone tumor involving the right frontal region of the
calvaria in one patient (Larnaout et al 2007) and nephro-
blastoma (Wilms tumor) in a second patient (Rogers et al
2010). On the other hand, a subsequent study in 21 Wilms
tumor tissues did not reveal increased L-2-HG levels, which
therefore did not directly relate L-2-HG with Wilms tumor
formation (Rakheja et al 2011). The possible association of
the metabolite L-2-HG and tumorigenesis requires further
investigation.
L2HGDH mutations: the molecular basis of L-2-HGA
Two research groups independently identified the gene as-
sociated with L-2-HGA. Rzem et al (2004) purified a dehy-
drogenase from rat liver that catalyzed the conversion of L-
2-HG to 2-KG. Various assay methodologies identified
Table 4 D-2-HG concentration
in body fluids and cultured
lymphoblasts of D-2-HGA
patients
(Gibson et al 1993b; Kranendijk









mean (n); range mean (n); range mean (n); range mean (n); range
Controls 6 (18); 2.8-17 0.7 (10); 0.3-0.9 0.1 (10); 0.07-0.3 0.11 (5); 0.06-0.13
D-2-HGA type I 969 (20); 103-2414 68 (7); 26-123 13 (3); 6-18 1.8 (2); 1.7-1.9
D-2-HGA type II 2486 (19); 448-11305 366 (9); 99-757 79 (4); 30-172 15.1 (5); 1.9-28.5
Table 5 Clinical observations in L-2-HGA reported in the literature
Barth et al 1992, 1993 Barbot et al 1997 Topcu et al 2005 Steenweg et al 2009, 2010
Number of patients- clinical description 12 6 29 106
Age onset After infancy ½-2 yr (100%) 1-10 yr (67%) 0-7 yr (97%)
11-18 yr (24%)
19-30 yr (7%)
Insidious onset + + +
Signs at diagnosis
developmental delay + (33%) + (83%) + + (52%)
epilepsy + (1 pt.) + (1 pt.) + (42%)
cerebellar ataxia + (1 pt.) + + (20%)
Signs during disease course
developmental delay + (100%) + (100%) + (79%) + (93%)
cerebellar ataxia + (92%) + (100%) + (66%) + (82%)
epilepsy + (50%) + (67%) + (41%) + (72%)
macrocephaly + (52%) + (48%)
extrapyramidal symptoms + (33%) + (38%)
Progression Chronic, slowly Slowly Static Slowly
Number of patients - brain MRI performed 10 6 24 56
Highly characteristic MRI abnormalities* + + + +
*Combination of predominantly subcortical cerebral white matter abnormalities and abnormalities of the dentate nucleus, globus pallidus, putamen,
and caudate nucleus
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several properties of the proposed L-2-hydroxyglutarate
dehydrogenase (L-2-HGDH) which facilitated database
searches and an eventual identification of the L2HGDH
gene (GeneBank 79944, NM_024884, MIM# 609584).
Subsequently, homozygosity mapping in three unrelated
consanguineous families with L-2-HGA confirmed the
association between the L2HGDH gene and L-2-hydrox-
yglutaric aciduria. An additional homozygosity mapping
study identified C14orf160, a gene carrying mutations in 21
confirmed L-2-HGA patients from 15 Turkish families
(Topcu et al 2004).
Numerous mutations in L2HGDH have now been
reported worldwide, summarized in a Mutation Update
(Steenweg et al 2010) and registered in the Leiden Open
Variation Database (www.LOVD.nl/L2HGDH 2011). Cur-
rently, 86 unique variants have been described in 164 indi-
viduals who are homozygous or compound heterozygous
(157 index, seven siblings) for these alleles. The majority of
variants are missense mutations that alter invariably con-
served amino acids.
Metabolism in L-2-HGA
L-2-HG is formed from 2-KG in a non-specific reaction
catalyzed by L-malate dehydrogenase (L-malDH, EC
1.1.1.37), which employs NADH as the hydride donor
(Fig. 7) (Rzem et al 2007). This reaction is hypothesized
to be an “unwanted” side reaction of L-malDH, which
normally catalyzes the conversion of L-malate to oxaloace-
tate in the TCA cycle. Accordingly, to prevent loss of
carbon moieties in the TCA cycle, and to protect against
potential toxic effects, L-2-HG is reconverted to 2-KG via
L-2-HGDH (EC 1.1.99.2), with FAD as cofactor. The role of
L-2-HGDH, therefore, appears to be that of a “repair”
mechanism for this unwanted side reaction of L-malDH,
since L-2-HG has no known physiological function in human.
L-2-HGA can thus be considered a “disorder of metabolite
repair” (Van Schaftingen et al 2008).
The biochemical hallmark of L-2-HGA is the accumula-
tion of urinary L-2-HG, which is 10 to 300 times increased
in comparison to controls (Table 6), but correlation of
excretion levels with disease severity have not been demon-
strated (Barbot et al 1997; Steenweg et al 2010). The rela-
tionship between molecular variants and biochemical
abnormalities (increased L-2-HG) in L-2-HGA was con-
firmed with a specific L-2-HGDH enzyme assay employing
stable isotope labeled L-[3,3,4,4-2H4]2-hydroxyglutaric acid
and LC-MS/MS (Kranendijk et al 2009). Impaired L-2-
HGDH enzyme activity was documented in fibroblasts,
lymphoblasts and lymphocytes derived from 15/15 L-2-
HGA patients, and in only one residual activity was detected
(20% of control). Of interest, this patient was compound
heterozygous for twomissensemutations, which is considered
a relatively mild genotype. On the other hand, some interest-
ing associations have been observed between L2HGDH var-
iants and urinary L-2-HG concentrations. Patients harboring
two missense mutations excreted 25-50% less L-2-HG than
those with two presumed null mutations (Table 6), suggesting
residual enzyme activity in the former group (Steenweg et al
2010). Transfection studies in human embryonic kidney cells
overexpressing human L2HGDH have confirmed the absence
of L-2-HGDH enzyme activity when pathogenic mutations
were incorporated (Rzem et al 2006). L-2-HG levels in plasma
and CSF are elevated as well, with a CSF/plasma ratio >1
(Table 7). This is contrarily to the findings in D-2-HGAwhere
D-2-HG concentrations in CSF are lower than in plasma (ratio
CSF/plasma <1, Table 4).
In addition to L-2-HGA, lysine is also moderately ele-
vated in CSF and plasma derived from patients (Table 7).
Increased urinary levels of lysine were identified in 4 out of
6 patients (Barbot et al 1997), but Barth et al (1993) failed to
demonstrate this abnormality in the cohort those investiga-
tors studied. Direct correlations between L-2-HG and lysine
levels in any physiological fluid have not been documented.
Kamoun et al (2002) noted that hyperlysinemia (MIM
#238700) is observed secondarily in disorders in which 2-
KG is decreased. Since the ε-amino group of lysine is trans-
aminated to 2-KG through the intermediate saccharopine to
form 2-aminoadipic semialdehyde and glutamic acid, repre-
senting a two step mitochondrial process involving alpha-
aminoadipic semialdehyde synthase (AASS), these authors
have suggested that lysine accumulation in L-2-HGA
reflects low mitochondrial 2-KG availability.
Pathophysiology of L-2-HGA
Exposure of rat brain tissues to increased L-2-HG signifi-
cantly inhibited creatine kinase activity in rat cerebellum
homogenates (da Silva et al 2003c), induced oxidative stress
(Latini et al 2003a) and increased glutamate uptake in syn-
aptosomes and synaptic vesicles (Junqueira et al 2003),
Fig. 7 L-2-HG is formed via the non-specific interaction of L-malDH
with 2-KG using NADH. The “enzyme of metabolite repair” L-2-
HGDH catalyzes the interconversion of L-2-HG to 2-KG using FAD
as cofactor. L-2-HG accumulates in L-2-HGA patients when L-2-
HGDH is impaired
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indicating a potential neurodegenerative effect of L-2-HG.
Similar results were previously observed with high levels of
D-2-HG, so this outcome is not specific for L-2-HG. Con-
versely, the characteristic pattern of brain MRI abnormali-
ties in L-2-HGA supports the hypothesis that a specific
pathophysiological mechanism exists in L-2-HGA, proba-
bly L-2-HG concentration-dependent, but this remains to be
conclusively demonstrated. The role of lysine accumulation
in the disease pathology remains uncertain, since hyperlysi-
nemia is observed in impaired AASS enzyme activity, a rare
metabolic disorder considered to be a “nondisease”, since
patients generally achieve normal intellectual performance
(Dancis et al 1983; Saudubray and Rabier 2007).
Therapeutic approaches
Specific therapeutic approaches in L-2-HGA have not been
reported, although two anecdotal reports have provided
provocative results and potential avenues for exploration.
L-2-HGA was documented in a 40-year-old female with
mild limb spasticity, marked dystonia of the neck and arms,
mild intellectual delay, and a homozygous mutation in
L2HGDH (Samuraki et al 2008). Brain MRI revealed dif-
fuse atrophy and leukoencephalopathy involving mainly
subcortical white matter. Intervention with FAD (30 mg/
day) and levocarnitine chloride (900 mg/day) was instituted,
resulting in gradual improvement in tremor and dystonia
within weeks. After six months of intervention, gait was
normal and urinary L-2-HG had decreased by 50%, and this
improvement was maintained for more than 4 years follow-
ing initiation of treatment.
The second patient was a 16-year-old boy with L-2-HGA
who presented developmental delay since infancy, but alter-
ations in L2HGDH were not reported. He was unable to
walk without support until 3 years of age (Yilmaz 2009),
associated with impaired language skills and difficulties
Table 6 Urinary L-2-HG
concentrations in reported
patients and controls
# Significant differences were
found between L-2-HGA patient
groups carrying a “mild”
missense mutation compared
to a “severe” presumed null
mutation, showing 25-50%
lower urinary L-2-HG levels in
the former group
L-2-HGA patients (n) Urinary L-2-HG (mmol/mol creat.) References
Controls (18) 1.3- 19 Gibson et al 1993a
L-2-HGA (9) 332-2742 Gibson et al 1993a
L-2-HGA (12) 226-4299 Barth et al 1993
L-2-HGA (7) 630-1420 Barbot et al 1997
L-2-HGA (29) 1000-5520 Topcu et al 2005
L-2-HGA (15) 671-3392 Kranendijk et al 2009
L-2-HGA (106) 350-3357 Steenweg et al 2010
L-2-HGA (mutations L2HGDH) Steenweg et al 2010
c.905C>T (6) 1090 p00.012#
c.530_533delinsATT (9) 2147
L-2-HGA (mutations L2HGDH) Steenweg et al 2010
missense mutations (28) 1431 p00.012#
presumed null mutations (28) 1916
Table 7 L-2-HG and lysine concentrations in urine, plasma and CSF of reported patients
Mean (n); range Urine (mmol/mol creatinine) Plasma (μmol/L) CSF (μmol/L)
Controls L-2-HGA Controls L-2-HGA Controls L-2-HGA
L-2-HG
Gibson et al 1993b 6 (18); 1.3-19 1283 (9); 332-2742 0.6 (10); 0.5-1.0 47 ( 8); 27-62 0.7 (10); 0.3-2.3 62 (6); 34-100
Barth et al 1993 <52 1810 (12); 226-4299 n.d. 31 (10); 7-84 n.d. 122 (6); 23-474
Barbot et al 1997 <15 1000 (6); 650-1420 - # - #
mean (n); range 1364 (27); 226-4299 39 (18); 7-84 92 (12); 23-474
Lysine
Gibson et al 1993b - - - - - -
Barth et al 1993 7-45 27 (4); 11-42 120-230 279 (8); 70-380 10-25 79 (6); 66-89
Barbot et al 1997 7-58 89 (6); 36-168 40-163 285 (6); 185-396 14-25 77 (2); 60, 95
n.d. 0 not detected; # increased values were detected in plasma and CSF in one patient, as well as an increased CSF/plasma ratio
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with hand movements. Cognitive function became in-
creasingly impaired with age. Intervention with ribofla-
vin (vitamin B2, precursor of FAD; 100 mg/day)
partially improved cognitive and motor performance
within days, and the urinary L-2-HG level decreased
by 75% within three months of treatment. Cessation of
riboflavin treatment resulted in significant decompensation
(including clinical symptoms and urinary L-2-HG excretion).
Reinstitution of riboflavin intervention returned the pa-
tient to his previously improved clinical picture within
days. His brain MRI showed leukodystrophic changes
prior to therapy, which remained unchanged after two
years of riboflavin intervention.
In contrast to these two patients, a two month therapeut-
ical trial with riboflavin (200 mg/day) was unsuccessful in a
9-year-old female with L-2-HGA (Jequier et al 2008). She
developed a progressive action tremor, light gait ataxia,
dysarthria and moderate mental retardation associated with
a homozygous splice site mutation in L2HGDH. L-2-HG
levels in physiological fluids remained unchanged, sug-
gesting that riboflavin was unable to augment a complete
absence of residual enzyme activity associated with the
splicing variant.
The fact that L-2-HGDH employs FAD as co-substrate
(Fig. 7) and that its enzyme increases with increasing FAD
concentrations (Rzem et al 2006), suggest that FAD acts in a
chaperone function to restore L-2-HGDH enzyme activity
and thereby reduces L-2-HGA excretion. Nevertheless, it
appears that this approach (FAD supplementation) is only
effective in “mild” missense mutations in L2HGDH as
found in the first patient, whereas truncated enzymes (pre-
sumed null mutations) are not responsive (Table 6). One
patient, having compound heterozygous missense mutations
in L2HGDH, was found to have modest residual L-2-HGDH
enzyme activity (Kranendijk et al 2009), but a therapeutic
trial with riboflavin has not been undertaken. Unfortunately,
riboflavin intervention is not expected to improve the
leukoencephalopathy observed in patients.
Combined D,L-2-hydroxyglutaric aciduria
Currently, six cases of D,L-2-hydroxyglutaric aciduria (D,L-
2-HGA) have been described, of which four were previously
classified as D-2-HGA affected with a severe phenotype
(Wagner et al 1998; Amiel et al 1999; Van der Knaap et al
1999a, b; Muntau et al 2000; Wajner et al 2002; Read et al
2005). D,L-2-HGA is biochemically characterized by mod-
erately increased D-2-HG and L-2-HG in urine, mild
increases of both metabolites in plasma, and a very slight
elevation of D-2-HG in CSF and normal levels of L-2-HG
(Table 8). D-2-HG concentration exceeds L-2-HG in all
fluids, while lactate and TCA cycle metabolites (succinate,
fumarate and malate) were variably increased in urine,
and 2-ketoglutarate was consistently increased in four
patients (A-D).
Five patients (A-D, F) manifested a consistent clinical
picture encompassing severe neonatal epileptic encephalop-
athy, often accompanied by respiratory insufficiency requir-
ing artificial ventilation (Table 9). Four probands died
within the first year, and the fifth at 3.5 years. The brain
MRI of all revealed enlarged ventricles, subependymal
pseudocysts and delayed gyration and myelination. Patient
E additionally manifested hypotonia, developmental delay,
seizures, cardiomyopathy and respiratory distress, with a
brain MRI suggestive of mitochondrial disease (Wajner
et al 2002). The patient expired at 10 months of age in
cardiogenic shock. The clinical features of patient E
show similarities with D-2-HGA type II, although the
increased L-2-HG and brain MRI abnormalities deviate
with those of D-2-HGA type II. Therefore we speculate
that the etiology in this patient is different from that of
the other patients.
We speculate that increased 2-KG in patients with D,L-2-
HGA lead to the formation of D-2-HG and L-2-HG via
HOT and L-malDH activities (Fig. 3). Nonetheless, the
D,L-2-HGA disorder appears distinct from D-2-HGA and
L-2-HGA, with respect to the much lower level of both
isomers in physiological fluids, as well as the presence of
increased lactate and TCA cycle intermediates (2-KG,
succinate, fumarate and malate), suggestive of mitochondrial
dysfunction. No mutations were detected in either D2HGDH,
L2HGDH, or IDH (unpublished data) from patients B and F.
We speculate that the mode of inheritance in D,L-2-HGA is
autosomal recessive since patients C and D were from a
consanguineous union. Currently, treatment options are
unavailable for combined D,L-2-HGA.
Other disorders with accumulation of 2-HG
Neoplastic disorders with IDH mutations
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1,
IDH2), confer on these enzymes a new function, namely
the capacity to convert 2-KG to D-2-HG (Parsons et al
2008; Dang et al 2009; Ward et al 2010). This mechanism
is identical to that observed in D-2-HGA type II. Con-
sequently, elevated D-2-HG has been observed in sam-
ples of malignant gliomas and tumor tissues (Dang et al
2009), as well as in cells and serum obtained from
acute myeloid leukemia patients (Ward et al 2010;
Gross et al 2010; Sellner et al 2010). All of these
pathological conditions showed mutations in either IDH1 or
IDH2. Many investigators suggest that D-2-HG is an onco-
metabolite, but this has not been proven.
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D-2-HGA in skeletal dysplasia (MIM# 271550)
Three patients with skeletal dysplasia manifested increased
D-2-HG excretion, a feature not previously reported in
either D-2-HGA type I or II. Talkhani et al (2000) reported
a patient with spondyloenchondrodysplasia and elevated D-
2-HG in urine and plasma, and normal L-2-HG concentra-
tion. The proband was diagnosed at 1 year with a crippling
form of skeletal dysplasia, and global developmental delay
that improved in her second year of life. The second patient
was a male infant diagnosed at 6 months with skeletal
dysplasia, and mild motor and mental delay (Honey et al
2003). Urinalysis revealed increased D-2-HG. At 11 months
the cardinal clinical feature was spondyloenchondrodyspla-
sia associated with hypotonia, delayed fine motor function,
and severely delayed speech development. Brain MRI
revealed moderate dilatation of the lateral ventricles, a large
cavum septi pellucidi and cavum vergae, with normal white
matter maturation. The third proband was a 17-month-old
boy with waddling gait and swollen joints, whose motor and
mental development (other than delayed walking) was nor-
mal at 3 years of age (Bayar et al 2005). A bone survey
Table 8 Biochemical findings in combined D,L-2-HGA patients reported in the literature
Patient Urine (mmol/mol creatinine) Plasma (μmol/L) CSF (μmol/L)
D-2-HG L-2-HG D-2-HG L-2-HG D-2-HG L-2-HG
Controls 2.8-17 1.3-19 0.3-0.9 0.5-1.0 0.07-0.3 0.3-2.3
A 315-1185 162-332 2.5 2.3-3.7 2.5 1.2
B 520 142 2.22 1.07 0.49 normal
C* 228 145 – – – –
D* 17.9-1072 25.2-430 2.48 2.22 0.42 normal
E 632, 685, 786 32, 76, 83 – – – –
F 162, 306 127, 152 1.8, 4.6 1.91, 1.7 – –
mean (n); range 496 (6); 228-750 161 (6); 64-247 2.6 (4); 2.2-3.2 2.0 (4); 1.1-3.0 1.1 (3); 0.42-2.5 normal (3)
* Siblings; References: Controls-(Van der Knaap et al 1999a); A-(Wagner et al 1998) case2, (Van der Knaap et al 1999b) pat.8, (Muntau et al 2000)
pat.3; B-(Amiel et al 1999) case2, (Van der Knaap et al 1999a) pat.4; C-(Muntau et al 2000) pat.1, (Van der Knaap et al 1999a) pat.1; D-(Muntau et
al 2000) pat.2, (Van der Knaap et al 1999a) pat.2; E-(Wajner et al 2002); F-(Read et al 2005)
Table 9 Clinical observations in D,L-2-HGA patients reported in the literature
Patient A Patient B Patient C* Patient D* Patient E Patient F
Gender Female Female Male Female Male Female
Age at death 8 months <11 months 3.5 years 2.5 months 10 months 1 month
Consanguinity - - + + - -
Epileptic encephalopathy + + + + + +
Developmental delay Severe Severe Severe Severe Severe Severe




Brain MRI abnormalities + + + Not performed Suggestive of mitochondrial
disease#
+
Enlarged ventricles + + + +
Subependymal pseudocysts + + + +
Delayed gyration and
myelination
+ + + +
References Wagner et al
1998








* Siblings; # Brain MRI revealed bilateral lesions in the substantia nigra, the periaqueductal area, the medial part of the thalamus, the
hypothalamus, the caudate nucleus, putamen and globus pallidus
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revealed severe metaphyseal widening, splaying, cupping and
fragmentation. D-2-HG was elevated in the urine on two
occasions. The clinical and metabolic similarities led Bayar
and colleagues to label it as “metaphyseal enchondrodysplasia
with D-2-hydroxyglutaric aciduria”, since this cohort of
patients distinctly differ radiographically and biochemically
from other cases of spondyloenchondrodysplasia.
Very recently, Vissers et al (2011) detected in four
patients affected with metaphyseal chondromatosis and D-
2-hydroxyglutaric aciduria (MC-HGA), including the pa-
tient reported by Bayar et al, somatic mutations of IDH1
(p.Arg132His, p.Arg132Ser) using exome sequencing of
blood DNA. These somatic mutations in IDH1 may explain
all features of MC-HGA, including the sporadic occurrence,
metaphyseal disorganization and chondromatosis, urinary
excretion of D-2-HG, and reduced cerebral myelinization.
Multiple Acyl-CoA dehydrogenase deficiency
(MADD, MIM# 231680, glutaric aciduria type II)
MADD is an autosomal recessively-inherited disorder of
fatty acid, amino acid, and choline metabolism (Olsen et al
2007; Liang et al 2009). MADD can result from defects in
two flavoproteins: electron transfer flavoprotein (ETF) or
ETF:ubiquinone oxidoreductase (ETF:QO). ETF is an elec-
tron acceptor for several dehydrogenases, subsequently trans-
ferring these to ETF-QO which then moves these electrons to
ubiquinone further along in the respiratory chain. In MADD,
glutaric aciduria is the biochemical hallmark, the elevated D-
2-HG is often observed in urine. The pathophysiology is
thought to involve impaired D-2-HGDH activity, since it
cannot transfer its electrons to defective ETF or ETF:QO.
Succinic semialdehyde dehydrogenase deficiency
(SSADH, MIM# 271980)
SSADH deficiency is an autosomal recessively inherited dis-
order caused by mutations in the SSADH gene (Jakobs et al
1993; Akaboshi et al 2003). SSADH catalyzes the conversion
of succinic semialdehyde (SSA) to succinic acid (SA). SSA
accumulates and is converted to 4-hydroxybutyrate (GHB) via
SSA-reductase. GHB represents the biochemical hallmark of
this disease. The proposed pathophysiology is that elevated
intracellular GHB drives the HOT reaction to form SSA and
increased D-2-HG in stoichiometric conversion from 2-KG
(Fig. 3) (Struys et al 2006).
Miscellaneous disorders related with 2-HG
Other disorders show increased levels of 2-HG (undifferenti-
ated for D-2-HG or L-2-HG, or combined accumulation of
both), often related to a primary accumulation of 2-KG. For
example, DOOR-syndrome (an autosomal recessive malfor-
mation syndrome) variably features elevated urinary 2-KG and
2-HG (James et al 2007). Also dihydrolipoyl dehydrogenase
(E3) deficiency manifests increased levels of many organic
acids, including 2-KG and 2-HG (Kuhara et al 1983).
Final remarks
The inborn 2-hydroxyglutaric acidurias represent distinct
neurometabolic disorders for which the underlying etiology
is only beginning to be revealed (summarized in Table 10
and supplemented with a diagnostic flow chart in Fig. 8).
Fig. 8 Diagnostic flow chart
for 2-hydroxyglutaric acidurias
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Although the D-, L- and combined disorders appear to form
distinct clinical diseases, we remain hampered in our under-
standing of their pathophysiology, because the role of the
metabolites themselves remains unclear. Specific metabolic
pathways for these chiral intermediates are largely un-
known, and their role in the central nervous system remains
to be defined. The development of models (yeast, zebrafish,
mouse) in which the specific genes are ablated/mutated
(D2HGDH, L2HGDH, IDH1, IDH2) may help us to under-
stand the associated biochemistry. Nonetheless, the current
work has set the foundation for a more comprehensive
understanding of these disorders, based upon clinical, meta-
bolic, enzymatic and genetic characterization. As is the case
with most “new” neurometabolic disorders, the heterogeneity
of phenotypic/genotypic presentations is likely to expand as
our knowledge of the disorders grows. Accurate working
models combined with low-threshold screening can provide
clues to therapeutic strategies.
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